Should phenytoin or barbiturates be used as second-line anticonvulsant therapy for toxicological seizures

Clinical Toxicology

Volumn 48, Issue 8, 2010, Pages 800-805

  Shah, Anoop S V ^a   Eddleston, Michael ^a,b  

^a ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Barbiturates; Drug induced seizures; Phenobarbital; Phenytoin; Toxin induced seizures

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; BARBITURIC ACID DERIVATIVE; CHLORIDE CHANNEL; CLONAZEPAM; COCAINE; DIAZEPAM; ETIRACETAM; FOSPHENYTOIN SODIUM; LORAZEPAM; MIDAZOLAM; ORGANOPHOSPHORUS COMPOUND; PENICILLIN G; PENTOBARBITAL; PHENOBARBITAL; PHENYTOIN; PILOCARPINE; PROPOFOL; THIOPENTAL; VALPROIC ACID; VOLTAGE GATED SODIUM CHANNEL;

ANTICONVULSANT ACTIVITY; ARTICLE; CARDIOTOXICITY; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG MEGADOSE; EPILEPTIC STATE; HEART ARRHYTHMIA; HUMAN; HYPOTENSION; LOADING DRUG DOSE; LOW DRUG DOSE; NERVE CELL EXCITABILITY; NONHUMAN; RESPIRATION DEPRESSION; SEIZURE; SELF POISONING; SYSTEMATIC REVIEW; TREATMENT RESPONSE; CHEMICALLY INDUCED; SEIZURES;

ANIMALIA;

BARBITURATES; HUMANS; PHENYTOIN; SEIZURES;

EID: 77958553460     PISSN: 15563650     EISSN: 15569519     Source Type: Journal    
DOI: 10.3109/15563650.2010.521506     Document Type: Article

References (51)

1. Thundiyil JG, Kearney TE, Olson KR. Evolving epidemiology of drug-induced seizures reported to a poison control center system. J Med Toxicol 2007; 3:15-19.
2. Lowenstein DH. Status epilepticus: an overview of the clinical problem. Epilepsia 1999; 40(Suppl. 1):S3-S8.
3. Roberts DM, Dissanayake W, Rezvi Sheriff MH, Eddleston M. Refrac-tory status epilepticus following self-poisoning with the organochlorine pesticide endosulfan. J Clin Neurosci 2004; 11:760-762.
4. Starreveld E, Hope E. Cicutoxin poisoning (water hemlock). Neurology 1975; 25:730-734.
5. Wallace KL. Toxin-induced seizures In: Brent J, Wallace K, Burkhart K, eds. Critical Care Toxicology: Diagnosis and Management of the Critically Poisoned Patient. Philadelphia, Pennsylvania: Elsevier Mosby; 2005:225-239.
6. McNamara JO. Drugs effective in the therapy of the epilepsies. In: Hardman JG, Limbird LE, Gilman GA, eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 10th ed. New York: McGraw Hill; 2001:521-547.
7. Fisher RS. Animal models of the epilepsies. Brain Res Brain Res Rev 1989; 14:245-278.
8. Victor M, Ropper AH, eds. Epilepsy and other seizure disorders. In: Adams and Victor's Principles of Neurology. 7th ed. New York: McGraw-Hill; 2001. 331-365.
9. Daly FF, Little M, Murray L. A risk assessment based approach to the management of acute poisoning. Emerg Med J 2006; 23:396-399.
10. Bey AT, Walter FG. Seizures. In: Ford M, Delaney KA, Ling L, Erickson T, eds. Clinical Toxicology. Philadelphia, Pennsylvania: Saunders; 2001:155-167.
11. Rao RB. Neurologic principles. In: Flobenbaum N, Goldfrank L, Hoffman R, Howland MA, Lewin N, eds. Goldfrank Toxicologic Emer-gencies, 8th ed. New York: McGraw-Hill Professional; 2006:307-328.
12. Bronstein AC, Spyker DA, Cantilena LR Jr., Green JL, Rumack BH, Giffin SL. 2008 annual report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 26th annual report. Clin Toxicol (Phila) 2009; 47:911-1084.
13. Bronstein AC, Spyker DA, Cantilena LR Jr., Green JL, Rumack BH, Heard SE. 2007 annual report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 25th annual report. Clin Toxicol (Phila) 2008; 46:927-1057.
14. Bronstein AC, Spyker DA, Cantilena LR Jr., Green J, Rumack BH, Heard SE. 2006 annual report of the American Association of Poison Control Centers' National Poison Data System (NPDS). Clin Toxicol (Phila) 2007; 45:815-917.
15. Wood DM, Rajalingam Y, Greene SL, Morgan PE, Gerrie D, Jones AL, Dargan PI. Status epilepticus following intentional overdose of fluvox-amine: a case report with serum fluvoxamine concentration. Clin Toxicol (Phila) 2007; 45:791.
16. Prasad K, Al Roomi K, Krishnan PR, Sequeira R. Anticonvulsant ther-apy for status epilepticus. Cochrane Database Syst Rev 2005; CD003723.
17. Sofia RD, Gordon R, Gels M, Diamantis W. Effects of felbamate and other anticonvulsant drugs in two models of status epilepticus in the rat Res Commun Chem Pathol Pharmacol 1993; 79:335-341.
18. Turski WA, Cavalheiro EA, Coimbra C, da Penha BM, Ikonomidou-Turski C, Turski L. Only certain antiepileptic drugs prevent seizures induced by pilocarpine. Brain Res 1987; 434:281-305.
19. Derlet RW, Albertson TE. Anticonvulsant modification of cocaine-induced toxicity in the rat Neuropharmacology 1990; 29:255-259.
20. Goldberg MJ, Spector R, Miller G. Phenobarbital improves survival in theophylline-intoxicated rabbits. J Toxicol Clin Toxicol 1986; 24:203-211.
21. Weihrauch T, Rieger H, Köhler H. Influence of diazepam and pheny-toin on penicillin induced cerebral convulsion. Arzneimittelforschung 1976; 26:104-108.
22. Amabeoku GJ, Farmer CC. Gammaaminobutyric acid and mefloquine-induced seizures in mice. Prog Neuropsychopharmacol Biol Psychiatry 2005; 29:917-921.
23. Hoffman A, Pinto E, Gilhar D. Effect of pretreatment with anticonvul-sants on theophylline-induced seizures in the rat J Crit Care 1993; 8:198-202.
24. Sawaki K, Ohno K, Miyamoto K, Hirai S, Yazaki K, Kawaguchi M. Effects of anticonvulsants on local anaesthetic-induced neurotoxicity in rats. Pharmacol Toxicol 2000; 86:59-62.
25. Beaubien AR, Carpenter DC, Mathieu LF, MacConaill M, Hrdina PD. Antagonism of imipramine poisoning by anticonvulsants in the rat Toxicol Appl Pharmacol 1976; 38:1-6.
26. Blake KV, Massey KL, Hendeles L, Nickerson D, Neims A. Relative efficacy of phenytoin and phenobarbital for the prevention of theophyl-line-induced seizures in mice. Ann Emerg Med 1988; 17:1024-1028.
27. Shih T, McDonough JH Jr., Koplovitz I. Anticonvulsants for soman-induced seizure activity. J Biomed Sci 1999; 6:86-96.
28. Zivanovic D, Stanojlovic O, Susic V, Stojanovic J. The effects of phenytoin and phenobarbital on seizures induced by imipenem/cilasta-tin in rats. Acta Neurol 2004; 104:20-26.
29. Grundy HF, Howarth F. Pharmacological studies on hemlock water dropwort Br J Pharmacol Chemother 1956; 11:225-230.
30. Lowenstein DH, Alldredge BK. Status epilepticus. N Engl J Med 1998; 338:970-976.
31. Treiman DM, Meyers PD, Walton NY, Collins JF, Colling C, Rowan AJ, Handforth A, Faught E, Calabrese VP, Uthman BM, Ramsay RE, Mamdani MB. A comparison of four treatments for generalized convul-sive status epilepticus. Veterans Affairs Status Epilepticus Cooperative Study Group. N Engl J Med 1998; 339:792-798.
32. Leppik IE, Derivan AT, Homan RW, Walker J, Ramsay RE, Patrick B. Double-blind study of lorazepam and diazepam in status epilepticus. JAMA 1983; 249:1452-1454.
33. Treatment of Convulsive Status Epilepticus. Recommendations of the Epilepsy Foundation of America's Working Group on Status Epilepticus. JAMA 1993; 270:854-859.
34. Shaner DM, McCurdy SA, Herring MO, Gabor AJ. Treatment of sta-tus epilepticus: a prospective comparison of diazepam and phenytoin versus phenobarbital and optional phenytoin. Neurology 1988; 38:202-207.
35. Guidelines for treating status epilepticus in adults and children. NICE Guidelines 2004.
36. Mayer SA, Claassen J, Lokin J, Mendelsohn F, Dennis LJ, Fitzsimmons BF. Refractory status epilepticus: frequency, risk factors, and impact on outcome. Arch Neurol 2002; 59:205-210.
37. Williams JD, ed. Chemotherapy. New York: Plenum Press; 1976:339-344.
38. Lallement G, Dorandeu F, Filliat P, Carpentier P, Baille V, Blanchet G. Medical management of organophosphate-induced seizures. J Physiol Paris 1998; 92:369-373.
39. Boucher BA. Fosphenytoin: a novel phenytoin prodrug. Pharmacotherapy 1996; 16:777-791.
40. Eriksson K, Keranen T, Kalviainen R. Fosphenytoin. Expert Opin Drug Metab Toxicol 2009; 5:695-701.
41. Chua HC, Venketasubramanian N, Tan CB, Tjia H. Paradoxical sei-zures in phenytoin toxicity. Singapore Med J 1999; 40:276-277.
42. Osorio I, Burnstine TH, Remler B, Manon-Espaillat R, Reed RC. Phenytoin-induced seizures: a paradoxical effect at toxic concentrations in epileptic patients. Epilepsia 1989; 30:230-234.
43. Trevor AJ, Way WL. Sedative hypnotic drugs. In: Katzung B, ed. Basic & Clinical Pharmacology, 10 ed. New York: McGrawHill; 2007.
44. Trapani G, Latrofa A, Franco M, Altomare C, Sanna E, Usala M, Biggio G, Liso G. Propofol analogues. Synthesis, relationships between structure and affinity at GABAA receptor in rat brain, and differential electrophysiological profile at recombinant human GABAA receptors. J Med Chem 1998; 41:1846-1854.
45. Prasad A, Worrall BB, Bertram EH, Bleck TP. Propofol and midazolam in the treatment of refractory status epilepticus. Epilepsia 2001; 42:380-386.
46. Payne TA, Bleck TP. Status epilepticus. Crit Care Clin 1997; 13:17-38.
47. Rossetti AO, Reichhart MD, Schaller MD, Despland PA, Bogous-slavsky J. Propofol treatment of refractory status epilepticus: a study of 31 episodes. Epilepsia 2004; 45:757-763.
48. Stecker MM, Kramer TH, Raps EC, O'Meeghan R, Dulaney E, Skaar DJ. Treatment of refractory status epilepticus with propofol: clinical and pharmacokinetic findings. Epilepsia 1998; 39:18-26.
49. Knake S, Gruener J, Hattemer K, Klein KM, Bauer S, Oertel WH, Hamer HM, Rosenow F. Intravenous levetiracetam in the treatment of benzodiazepine refractory status epilepticus. J Neurol Neurosurg Psychiatry 2008; 79:588-589.
50. Moddel G, Bunten S, Dobis C, Kovac S, Dogan M, Fischera M, Dziewas R, Schabitz WR, Evers S, Happe S. Intravenous levetiracetam: a new treatment alternative for refractory status epilepticus. J Neurol Neurosurg Psychiatry 2009; 80:689-692.
51. Eue S, Grumbt M, Muller M, Schulze A. Two years of experience in the treatment of status epilepticus with intravenous levetiracetam. Epilepsy Behav 2009; 15:467-469.